We have recently tested the hypothesis that MM-121 abrogates erbB3 signaling-mediated resistance to trastuzumab and paclitaxel in erbB2+ breast cancer cells via inactivation of erbB3 and its downstream PI-3 K/Akt signaling. This evidence concerns the gene ERBB2 and breast cancer.